IgG4-related disease: It's one of the most baffling conditions ever to puzzle a rheumatologist. In their three-part series, Zachary Wallace MD and John Stone MD of Harvard Medical Center, present (among many other revelations) an infographic showing the culprit's known whereabouts and a quiz to help you learn to track the diagnosis. Follow the trail of clues starting here.
In a randomized trial the anti-TNF antibody infliximab did not reduce resistance to IVIG treatment in Kawasaki disease. But it did reduce adverse reactions and improve secondary outcomes while being well-tolerated.
For the second time, an interleukin-6 receptor-α inhibitor has proven no better than placebo against ankylosing spondylitis in a randomized trial. The highest dose of sarilumab was most effective, but not effective enough to pass muster.
Congratulations! In our last installment, despite the odds, you (presumably) reached the correct verdict: The villain responsible for your patient's misery is indeed IgG4-related disease, not one of the many other suspects. Now, what's the sentence?
In Chapter I, you read the history and baffling description of IgG4-Related Disease, which goes by so many disguises, and learned of its previously known whereabouts. Herein, you have the opportunity to track it by solving a series of challenges.
IgG4-Related Disease (IgG4-RD): one of the most perplexing culprits ever to defy a rheumatologist. Here, we present a few basics about its shadowy past and its current known identity. Later Chapters in our series will invite you to track the diagnosis yourself and to discover the best treatment strategies.